Conmed Return on Equity (ROE) Growth & History (CNMD)

Conmed's return on equity was 4.72% for fiscal 2025.

View full Conmed company overview

Conmed annual return on equity history

Conmed annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-314.72%−10.02 pp
20242024-12-3114.74%+6.58 pp
20232023-12-318.16%+18.69 pp
20222022-12-31−10.53%−18.90 pp
20212021-12-318.37%+7.03 pp
20202020-12-311.34%−2.83 pp
20192019-12-314.17%−2.15 pp
20182018-12-316.32%−2.84 pp
20172017-12-319.16%+6.64 pp
20162016-12-312.52%−2.71 pp
20152015-12-315.23%−0.19 pp
20142014-12-315.42%−0.50 pp
20132013-12-315.92%−0.94 pp
20122012-12-316.86%+6.73 pp
20112011-12-310.13%−5.09 pp
20102010-12-315.22%

Conmed return on equity trends

Over the last five fiscal years, Conmed's return on equity increased from 1.34% to 4.72%, a change of +3.37 percentage points. The latest reported quarter, Q2 2026, shows 2.24%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Conmed source filings ↗

Community posts

It’s quiet here.

No posts about CNMD yet. Start the conversation.

Write the first post